ResearcherHippocration General HospitalNo recent work listed
Dimitrios G. Pectasides
Matched on ORCID iD 0000-0002-2102-2167; OpenAlex author ID A5012112204. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper
Papers 4
- Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers13020198↗
- Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents ta… Co-author DOI 10.1136/esmoopen-2019-000525↗
- Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Gr… Co-author DOI 10.1007/s11523-018-0605-y↗
- Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer. Co-author DOI 10.21873/anticanres.11232↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christos Dervenis · 4 shared papers, 2016–2021 · strength 0.28
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198↗
- Paper Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-pa… DOI 10.1136/esmoopen-2019-000525↗
- Paper Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Ca… DOI 10.1007/s11523-018-0605-y↗
- George Fountzilas · 4 shared papers, 2016–2021 · strength 0.28
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198↗
- Paper Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-pa… DOI 10.1136/esmoopen-2019-000525↗
- Paper Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Ca… DOI 10.1007/s11523-018-0605-y↗
- George E. Pentheroudakis · 3 shared papers, 2016–2019 · strength 0.19
- Paper Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-pa… DOI 10.1136/esmoopen-2019-000525↗
- Paper Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Ca… DOI 10.1007/s11523-018-0605-y↗
- Paper Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer. DOI 10.21873/anticanres.11232↗
- George Zarkavelis · 2 shared papers, 2019–2021 · strength 0.16
- Paper Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. DOI 10.3390/cancers13020198↗
- Paper Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-pa… DOI 10.1136/esmoopen-2019-000525↗
- Vasilios Karavasilis · 2 shared papers, 2018–2019 · strength 0.14
- Paper Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-pa… DOI 10.1136/esmoopen-2019-000525↗
- Paper Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Ca… DOI 10.1007/s11523-018-0605-y↗
- George Papaxoinis · 2 shared papers, 2016–2021 · strength 0.14
- Georgios Oikonomopoulos · 1 shared paper, 2021 · strength 0.09
- Elena Fountzilas · 1 shared paper, 2021 · strength 0.09
- Nikolaos K. Kentepozidis · 1 shared paper, 2021 · strength 0.09
- Philippos C. Patsalis · 1 shared paper, 2021 · strength 0.09
- Christos Agalianos · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.